EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers

Marco Russano, Giulia La Cava, Alessio Cortellini, Fabrizio Citarella, Alessandro Galletti iD, Giuseppina Rita Di Fazio, Valentina Santo, Leonardo Brunetti, Alessia Vendittelli, Iacopo Fioroni, Francesco Pantano, Giuseppe Tonini und 1 weitere

Current Oncology · 16.02.2023 · 30 (2) · 2366-2387

DOI: 10.3390/curroncol30020181 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 16.02.2023. Verfasst von Marco Russano und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 178 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy has revolutionized the treatment paradigm of non-small cell lung cancer and improved patients’ prognosis. Immune checkpoint inhibitors have quickly become standard frontline treatment for metastatic non-oncogene addicted disease, either as a single agent or in combination strategies. However, only a few patients have long-term benefits, and most of them do not respond or develop progressive disease during treatment. Thus, the identification of reliable predictive and prognostic biomarkers remains crucial for patient selection and guiding therapeutic choices. In this review, we provide an overview of the current strategies, highlighting the main clinical challenges and novel potential biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansImmunotherapyImmune Checkpoint InhibitorsBiomarkers, Tumor

Stichwörter der Autor:innen

PD-1/PD-L1 antibodiesbiomarkerscombination strategiesimmune checkpoint inhibitorsimmunotherapyliquid biopsynon-small cell lung cancertissue biomarkers

Substanzen

Immune Checkpoint InhibitorsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, Italy.
  • Division of Medical Oncology, San Camillo Forlanini Hospital, 00152 Roma, Italy.

ORCID-Profile: Alessandro Galletti

Zitieren

APA

Russano, M., La Cava, G., Cortellini, A., Citarella, F., Galletti, A., Di Fazio, G. R., Santo, V., Brunetti, L., Vendittelli, A., Fioroni, I., Pantano, F., Tonini, G., & Vincenzi, B. (2023). Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers. Current Oncology, 30(2), 2366-2387. https://doi.org/10.3390/curroncol30020181

Vancouver

Russano M, La Cava G, Cortellini A, Citarella F, Galletti A, Di Fazio GR, et al. Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers. Current Oncology. 2023;30(2):2366-2387. doi:10.3390/curroncol30020181

BibTeX
@article{Russano2023,
  author = {Russano, Marco and La Cava, Giulia and Cortellini, Alessio and Citarella, Fabrizio and Galletti, Alessandro and Di Fazio, Giuseppina Rita and Santo, Valentina and Brunetti, Leonardo and Vendittelli, Alessia and Fioroni, Iacopo and Pantano, Francesco and Tonini, Giuseppe and Vincenzi, Bruno},
  title = {Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers},
  journal = {Current Oncology},
  year = {2023},
  volume = {30},
  number = {2},
  pages = {2366--2387},
  doi = {10.3390/curroncol30020181}
}
Kostenlos starten →